In cystic fibrosis the symptoms of general obstruction of secretory organs and gastrointestinal tract, chronic progressive lung incapacitation and deranged transport of ions seem to be directly related to the modified glycoproteins and lipids in this disease. The projected studies are aimed to investigate the implications of the modified (overacylated with fatty acids) glycoproteins and the presence of ether lipid analogs in cystic fibrosis, to correlate the qualitative and quantitative results on lipids and glycoproteins with the pathological observations, to study the enzyme(s) involved in glycoprotein acylation (glycoprotein fatty acyl transferase(s)) and enzymes involved in regulation of the content of ether lipid analogs in the tissue (fatty acyl CoA reductase, fatty alcohol NAD+ oxidoreductase) and to correlate these findings with the health status of the patient. Further objectives of this proposal are to design a simple and reliable assay of fatty acyl transferase, or fatty acyl CoA reductase, or fatty alcohol NAD+ oxidoreductase using readily available specimens of the human tissue or fluids (skin biopsies, blood, amniotic fluid) which might be adopted for screening and for diagnostic purposes. The mucus glycoprotein will be isolated by combination of the organic solvent extraction, gel filtration and CsCl equilibrium density gradient centrifugation, and then analyzed for the content of covalently bound fatty acids. Using combination of chemical methods and proteases, the site(s) of fatty acid substitution will be determined. The glycoprotein, after release of fatty acids and deglycosylation, will be used as a substrate in the fatty acyl transferase(s) assay. The lipids isolated from samples prior to glycoprotein preparation will be separated into the individual components by means of thin layer chromatography, followed by analyses for the ether lipid analogs. Using palmitoyl (C14) CoA and (C14) hexadecanol the activity of fatty acyl transferase(s), fatty acyl CoA reductase, and fatty alcohol NAD+ oxidoreductase will be determined.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL032553-02
Application #
3343918
Study Section
Biochemistry Study Section (BIO)
Project Start
1985-02-01
Project End
1990-01-31
Budget Start
1986-02-01
Budget End
1987-01-31
Support Year
2
Fiscal Year
1986
Total Cost
Indirect Cost
Name
New York Medical College
Department
Type
Schools of Medicine
DUNS #
City
Valhalla
State
NY
Country
United States
Zip Code
10595
Nadziejko, C E; Slomiany, B L; Slomiany, A (1993) Most of the lipid in purulent sputum is bound to mucus glycoprotein. Exp Lung Res 19:671-84
Slomiany, A; Slomiany, B L (1992) Synthesis and macromolecular organization of gastrointestinal mucin. J Physiol Pharmacol 43:115-38
Slomiany, A; Okazaki, K; Tamura, S et al. (1991) Identity of mucin's ""118-kDa link protein"" with fibronectin fragment. Arch Biochem Biophys 286:383-8
Slomiany, B L; Nishikawa, H; Piotrowski, J et al. (1989) Lipolytic activity of Campylobacter pylori: effect of sofalcone. Digestion 43:33-40
Slomiany, B L; Kasinathan, C; Slomiany, A (1989) Lipolytic activity of Campylobacter pylori: effect of colloidal bismuth subcitrate (De-Nol) Am J Gastroenterol 84:1273-7
Slomiany, B L; Piotrowski, J; Okazaki, K et al. (1989) Nature of the enhancement of the protective qualities of gastric mucus by sucralfate. Digestion 44:222-31
Slomiany, A; Okazaki, K; Piotrowski, J et al. (1989) In vitro sulfation of sublingual salivary gland mucin: structures of 35S-labeled oligosaccharides. Biochem Int 18:589-97
Slomiany, B L; Murty, V L; Piotrowski, J et al. (1989) Effect of antiulcer agents on the physicochemical properties of gastric mucus. Symp Soc Exp Biol 43:179-91
Gwozdzinski, K; Slomiany, A; Nishikawa, H et al. (1988) Gastric mucin hydrophobicity: effects of associated and covalently bound lipids, proteolysis, and reduction. Biochem Int 17:907-17
Murty, V L; Slomiany, A; Zalesna, G et al. (1988) Prostaglandin effect on the enzymatic sulfation of mucus glycoprotein in gastric mucosa. Biochem Pharmacol 37:3311-6

Showing the most recent 10 out of 26 publications